Literature DB >> 12038593

Can we measure serum thyroglobulin?

P M Clark1, G Beckett.   

Abstract

Measurement of serum thyroglobulin (Tg) by immunoassay is used to monitor the treatment of differentiated thyroid cancer. An understanding of the disease process and the biochemistry of Tg allows the laboratory to determine the characteristics of suitable Tg assays. There are a number of key analytical issues: standardization, long-term assay stability, minimum detection limit, working range and the effect of endogenous Tg antibodies (TgAb). There are significant limitations to the methods used to determine TgAb interference. Clinicians should be aware of the limitations of immunoassays for this tumour marker.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12038593     DOI: 10.1258/0004563021902125

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  4 in total

1.  Evaluation of Different Methods for the Detection of Anti- Thyroglobulin Autoantibody: Prevalence of Anti-Thyroglobulin Autoantibody and Anti-Microsomal Autoantibody in Thyroid Cancer Patients.

Authors:  Chandrakala Gholve; Archana Damle; Savita Kulkarni; Sharmila Banerjee; Mgr Rajan
Journal:  Indian J Clin Biochem       Date:  2021-10-11

2.  Comparison of the influence of thyroglobulin antibodies on serum thyroglobulin values from two different immunoassays in post surgical differentiated thyroid carcinoma patients.

Authors:  Marijana Stanojevic; Svetlana Savin; Dubravka Cvejic; Aleksandar Djukic; Marija Jeremic; Snezana Zivancević Simonovic
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 3.  Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.

Authors:  Chao Ma; Anren Kuang; Jiawei Xie
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

4.  RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma.

Authors:  Maomei Ruan; Yan Shen; Libo Chen; Minghua Li
Journal:  Oncol Lett       Date:  2013-06-25       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.